
NYSE:CVS
All healthcare companies starting in pharmacies have been vertically segments like insurance, but they've had a tough time, because pharmacies are low-margin and getting tougher. Also, governments are getting more involved in drug pricing. Thirdly, post Covid medical procedures remain high which also squeezes margins. He exited CVS 6-8 months ago.
Market getting tired of missed earnings estimates. Company having trouble keeping sales up across business lines. However, retail presence and business overall still presenting value. Is one of the strong remaining brands left in the retail health companies. If company does not do any more M&A, and keeps balance sheet strong - should be ok. Expecting higher earnings going forward. Will continue to hold.
Reported earnings, stock came down. Will remain in penalty box for a couple of quarters. In a good sector, but continues to make missteps. Value trap right now. Over time should trend back up to $70, but you might be waiting a while.
Gets lumped in with WBA, but they're different businesses. Not keen on either right now, but he'd have a slight preference for CVS, as he knows it better.
Stable, much more broadly diversified than WBA. Way ahead of the curve on getting into homecare. Becoming a one-stop, end-to-end healthcare business. Generating free, excess cashflow that they're using for acquisitions without having to issue more shares. Dividend is more than secure, seeing share buybacks again.
Pharmacy side not doing well, as people are switching to online. Pharmacy benefits are doing OK. Basing since May. Seems to be trying to get above water; just today got above the 200-day MA. See if it stays there.
Long term, managed care might be where they'll be OK. Valuation discount in the stock price, but it's a value trap. 9-10x forward earnings, but growth rate is under 2%. He doesn't like to buy on activist shareholders getting in, because you don't really know what's going to happen. He buys based on numbers, with earnings growth in high single digits.